- $13.06bn
- $13.77bn
- $1.27bn
Tempus AI rises after surprise quarterly profit
Tempus AI Q3 revenue slightly beats estimates; raises guidance
Brief: Tempus Receives Ivdr Certification For Xr Rna Sequencing For Solid Tumor Profiling
Brief: Tempus Expands Strategic Collaboration With Bristol Myers Squibb
Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development
Moderna, Merck climb on collaboration with Tempus
Brief: Tempus Announces Multi-Year Collaboration With Moderna And Merck
Personalis slips as BTIG downgrades, sees no rival bid for Tempus deal
Brief: Tempus And Recursion Extend Existing Data License Agreement And Enter New License Agreement For Recursion’S RNA Foundation Model
Brief: Tempus Ai Founder Supports Anthropic CEO’S Call For Slowdown - Bloomberg News
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Tempus AI Inc reports results for the quarter ended June 30 - Earnings Summary
Tempus AI Q2 revenue slightly beats estimates
Personalis slips after Tempus AI strikes $1.5 bln takeover deal
Tempus to buy cancer test maker Personalis for $1.5 billion (updated)
Tempus to acquire Personalis for $1.5 billion
Brief: Biovica Refocuses US Commercial Strategy, Terminates Deal With Tempus AI
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple